New drug targets Hard-to-Treat cancers in people with BRCA2 or PALB2 mutations
NCT ID NCT04890613
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studies. Researchers will also look for signs that the drug shrinks tumors and monitor quality of life. About 52 participants will receive the drug by IV infusion twice per month.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CX-5461 (Pidnarulex), a drug given by IV infusion
What this could lead to
If successful, this could point toward a new treatment option for people with certain hard-to-treat cancers linked to BRCA2 or PALB2 mutations.
What could go wrong
This is an early Phase 1b trial with only 52 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is too soon to know if it will work for a broader population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Centre hospitalier de l'Université de Montréal (CHUM)
RECRUITINGMontreal, Quebec, H2X 0C2, Canada
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
H. Lee Moffitt Cancer Center and Research Institute Hospital
RECRUITINGTampa, Florida, 33612-9497, United States
Contact
-
Memorial Sloan-Kettering Cancer Center
WITHDRAWNNew York, New York, 10065, United States
-
Ohio State University-James Cancer Hospital and Solove Research Institute
RECRUITINGColumbus, Ohio, 43202, United States
Contact
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1X6, Canada
Contact
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
-
University of California, Los Angeles
RECRUITINGSanta Monica, California, 90404, United States
Contact